The Malignant Glioma drugs in development market research report provides comprehensive information on the therapeutics under development for Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malignant Glioma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malignant Glioma and features dormant and discontinued products.
GlobalData tracks 72 drugs in development for Malignant Glioma by 68 companies/universities/institutes. The top development phase for Malignant Glioma is phase ii with 20 drugs in that stage. The Malignant Glioma pipeline has 55 drugs in development by companies and 17 by universities/ institutes. Some of the companies in the Malignant Glioma pipeline products market are: Novartis, Osaka University and Immvira.
The key targets in the Malignant Glioma pipeline products market include DNA, Ephrin Type A Receptor 2, and DNA Topoisomerase II.
The key mechanisms of action in the Malignant Glioma pipeline product include DNA Synthesis Inhibitor with five drugs in Phase II. The Malignant Glioma pipeline products include 12 routes of administration with the top ROA being Oral and 12 key molecule types in the Malignant Glioma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Malignant Glioma overview
Malignant gliomas are aggressive and fast-growing tumors that arise from glial cells in the brain and spinal cord. Gliomas account for the most common type of primary brain tumors in adults. Symptoms of malignant gliomas vary depending on the tumor’s size, location, and rate of growth. Common symptoms may include headaches, seizures, cognitive changes, personality or behavior changes, weakness or sensory loss, and difficulties with balance or coordination.
For a complete picture of Malignant Glioma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
